HHS awards $544K for COVID-19/Flu/RSV test kits, raising questions on competition and value

Contract Overview

Contract Amount: $54,400 ($54.4K)

Contractor: Cepheid

Awarding Agency: Department of Health and Human Services

Start Date: 2026-09-16

End Date: 2027-09-15

Contract Duration: 364 days

Daily Burn Rate: $149/day

Competition Type: NOT COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: CEPHEID XPERT XPRESS COV-2/FLU/RSV PLUS TEST KITS

Place of Performance

Location: SUNNYVALE, SANTA CLARA County, CALIFORNIA, 94089

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $54,400 to CEPHEID for work described as: CEPHEID XPERT XPRESS COV-2/FLU/RSV PLUS TEST KITS Key points: 1. The contract for diagnostic test kits was awarded on a non-competitive basis, limiting price discovery. 2. The sole-source nature of this award warrants scrutiny regarding potential overpayment compared to market rates. 3. A lack of competition may indicate limited market availability or a strategic decision by the agency. 4. The contract duration of one year with a fixed-price structure provides cost certainty but may not capture volume discounts. 5. The specific product, CEPHEID XPERT XPRESS COV-2/FLU/RSV PLUS TEST KITS, suggests a focus on critical public health needs. 6. The Indian Health Service's procurement highlights the need for reliable diagnostic tools in underserved areas.

Value Assessment

Rating: questionable

Benchmarking the value for this specific diagnostic test kit is challenging without competitive bids. The fixed-price structure for a one-year period at $544,000 suggests a significant investment. Without comparative pricing data from other federal agencies or commercial entities for the same or similar kits, it's difficult to definitively assess if this represents a fair market price. The lack of competition is a primary driver for this questionable value assessment, as it removes the natural downward pressure on pricing that competitive bidding provides.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded as a sole-source purchase order, meaning it was not competed. The agency likely determined that only one source, Cepheid, could provide the specific diagnostic test kits required. This approach bypasses the standard competitive bidding process, which typically involves multiple vendors submitting proposals. The absence of competition means there was no opportunity to explore alternative suppliers or negotiate prices based on multiple offers, potentially leading to a higher cost for the government.

Taxpayer Impact: Taxpayers may have paid a premium due to the lack of competitive bidding. Without a competitive process, there's less assurance that the government secured the best possible price for these essential test kits.

Public Impact

Beneficiaries include patients served by the Indian Health Service, who will gain access to rapid diagnostic testing for COVID-19, Influenza, and RSV. The services delivered are the provision of critical in-vitro diagnostic test kits, enabling timely and accurate disease identification. The geographic impact is primarily focused on areas served by the Indian Health Service, likely including tribal communities and remote locations. Workforce implications include enabling healthcare providers within the IHS to efficiently diagnose and manage respiratory illnesses, potentially improving patient outcomes and reducing the spread of infections.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition and may result in higher costs for taxpayers.
Lack of transparency in the justification for sole-source procurement.
Potential for over-reliance on a single supplier for critical medical supplies.

Positive Signals

Ensures access to specific, potentially critical diagnostic technology for the Indian Health Service.
Fixed-price contract provides cost certainty for the duration of the award.
Addresses a clear public health need for multi-pathogen testing.

Sector Analysis

The market for in-vitro diagnostic (IVD) substances and testing equipment is a significant segment of the broader healthcare industry. This contract falls within the 'In-Vitro Diagnostic Substance Manufacturing' category, focusing on diagnostic kits. The market is characterized by innovation, regulatory oversight (FDA), and a mix of large established players and smaller specialized firms. Federal agencies, particularly those within HHS, are major purchasers of such supplies to support public health initiatives and healthcare delivery. Comparable spending benchmarks are difficult to establish without knowing the exact kit specifications and volume, but federal spending on diagnostic testing can run into billions annually.

Small Business Impact

This contract was not awarded to a small business, nor does it appear to include specific small business set-aside provisions. The sole-source nature of the award further limits opportunities for small businesses to participate as prime contractors. There is no explicit information provided regarding subcontracting plans that would involve small businesses. Therefore, the direct impact on the small business ecosystem from this specific contract appears minimal, though the broader availability of diagnostic tools can indirectly support small healthcare providers.

Oversight & Accountability

Oversight for this purchase order would typically fall under the Indian Health Service's procurement and financial management offices within HHS. Accountability measures are inherent in the purchase order process, requiring the contractor to deliver specified goods by a certain date. Transparency is limited due to the sole-source nature of the award; the justification for not competing the contract would be documented internally. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected in the procurement or execution of this contract.

Related Government Programs

COVID-19 Testing Supplies
Influenza Diagnostic Kits
Respiratory Syncytial Virus (RSV) Tests
Indian Health Service Medical Supplies
HHS Diagnostic Procurement

Risk Flags

Sole-source award
Lack of competitive bidding
Potential for inflated pricing
Limited transparency on justification

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $54,400 to CEPHEID. CEPHEID XPERT XPRESS COV-2/FLU/RSV PLUS TEST KITS

Who is the contractor on this award?

The obligated recipient is CEPHEID.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Indian Health Service).

What is the total obligated amount?

The obligated amount is $54,400.

What is the period of performance?

Start: 2026-09-16. End: 2027-09-15.

What is the specific justification provided by the Indian Health Service for awarding this contract on a sole-source basis?

The provided data indicates the contract was 'NOT COMPETED UNDER SAP' (Simplified Acquisition Procedures) and awarded as a 'PURCHASE ORDER'. While this signifies a non-competitive award, the specific justification for sole-sourcing is not detailed in the provided data. Typically, sole-source awards require a formal justification, such as the unique capability of a single contractor, urgent and compelling needs where competition is not feasible, or when only one responsible source exists. Without access to the agency's internal documentation or a public justification document (like a Justification for Other Than Full and Open Competition - JOFOC), the precise reason remains unknown. This lack of transparency is a common concern with sole-source procurements.

How does the price of these CEPHEID XPERT XPRESS test kits compare to market rates or similar federal contracts?

Direct price comparison is difficult without specific unit pricing and volume discounts. The total award is $544,000 for 364 days of supply. If we assume a roughly equal distribution over the year, this averages to approximately $1,491 per day for test kits. However, this doesn't reveal the per-kit cost, which is the most relevant metric. Given the sole-source nature, it's plausible that the price is higher than if it had been competitively bid. Federal agencies often negotiate volume discounts, which may not be fully realized in a sole-source award. Benchmarking against other federal contracts for similar diagnostic platforms or against commercial catalog prices would be necessary for a thorough value assessment, but this data is not provided.

What are the potential risks associated with relying on a single supplier for these critical diagnostic test kits?

The primary risk of relying on a single supplier (Cepheid, in this case) is supply chain vulnerability. Any disruption to Cepheid's manufacturing, distribution, or business operations could directly impact the Indian Health Service's ability to procure these essential test kits. This could lead to shortages, delays in patient care, and an inability to respond effectively to public health emergencies. Furthermore, a lack of competition removes the incentive for the sole supplier to offer competitive pricing or innovate rapidly, potentially leading to higher costs and less advanced technology over time compared to a more competitive market.

What is the track record of CEPHEID as a government contractor, particularly for similar diagnostic products?

Cepheid is a known entity in the diagnostic testing market, particularly for its GeneXpert systems, which are widely used for molecular diagnostics. They have a history of supplying diagnostic solutions to various entities, including government agencies. While specific details of their past performance on federal contracts are not provided here, their established presence suggests a level of experience. However, past performance does not guarantee future success or fair pricing, especially in a sole-source context. A deeper dive into their contract history, including past performance reviews and any disputes or issues, would be necessary for a comprehensive assessment.

How does this contract align with broader federal strategies for infectious disease preparedness and response?

This contract aligns with federal strategies by ensuring the Indian Health Service has access to rapid, multi-pathogen diagnostic capabilities. The ability to quickly test for COVID-19, Influenza, and RSV is crucial for effective disease surveillance, outbreak management, and patient treatment, especially within vulnerable populations served by the IHS. Such procurements contribute to the nation's overall preparedness by equipping healthcare providers with essential tools. However, the sole-source nature raises questions about the efficiency and cost-effectiveness of this alignment compared to a competitively procured solution.

What is the expected volume of tests to be performed under this contract, and how was this volume determined?

The provided data does not specify the expected volume of tests or the quantity of test kits to be procured. The total award amount of $544,000 and a duration of 364 days are given, but the number of kits or tests per kit is absent. This information is critical for calculating per-unit costs and assessing value for money. The determination of the required volume likely stems from the Indian Health Service's projected needs based on patient demographics, historical testing data, and anticipated disease prevalence within the communities they serve. Without this data, a detailed analysis of usage and cost per test is impossible.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Solicitation ID: 75H71026Q00082

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Danaher Corporation

Address: 904, EAST CARIBBEAN DRIVE, SUNNYVALE, CA, 94089

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $272,000

Exercised Options: $54,400

Current Obligation: $54,400

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Timeline